{"id":4047,"date":"2026-06-30T11:53:00","date_gmt":"2026-06-30T09:53:00","guid":{"rendered":"https:\/\/aquralabs.com\/?p=4047"},"modified":"2026-07-06T18:24:33","modified_gmt":"2026-07-06T16:24:33","slug":"selling-cosmetics-eu-us-safety-substantiation","status":"publish","type":"post","link":"https:\/\/aquralabs.com\/es\/selling-cosmetics-eu-us-safety-substantiation\/","title":{"rendered":"Selling Cosmetics in the EU and US: What Safety Substantiation Really Requires"},"content":{"rendered":"

When you say a cosmetic is \u00absafe,\u00bb EU and US regulators don’t hear a slogan. They hear a legal claim that has to be backed by structured data and expert judgement. This article compares what safety substantiation<\/strong> actually means under the EU Cosmetic Product Safety Report (CPSR) system and under US MoCRA, and shows how to build one safety package that satisfies both.<\/p>\n

The EU Model: CPSR and Pre-Market Safety Assessment<\/h2>\n

In the EU and the UK, you cannot legally place a cosmetic on the market without a Cosmetic Product Safety Report (CPSR)<\/strong> signed by a qualified safety assessor.<\/p>\n

\"Business<\/p>\n

Regulation (EC) No 1223\/2009 requires every cosmetic to undergo a safety assessment documented as a CPSR before it reaches consumers. The report follows a harmonised two-part structure recognised across the EU: Part A<\/strong> covers the safety information itself, composition, raw material specifications, impurities, microbiology, packaging, stability, toxicological profiles, exposure assessment and margin-of-safety calculations. Part B<\/strong> contains the assessor’s conclusion on safety under normal and foreseeable use, along with their reasoning and any conditions of use or warnings.<\/p>\n

The CPSR sits inside the Product Information File (PIF)<\/strong>, which must stay readily available to authorities and be maintained by the EU or UK Responsible Person<\/strong>. Because the safety opinion is issued before launch, it explicitly answers one question for the specific formula, packaging and use pattern: is this product safe under normal and reasonably foreseeable conditions of use?<\/p>\n

In practice, this means safety substantiation is formalised, centralised and front-loaded. No CPSR, no legal placing on the EU market.<\/strong><\/p>\n

The US Model: MoCRA and \u00abAdequate Substantiation of Safety\u00bb<\/h2>\n

MoCRA does not create a US clone of the CPSR, but it does turn safety substantiation into a clear, enforceable obligation rather than a \u00abnice to have.\u00bb<\/p>\n

Under MoCRA, the Responsible Person<\/strong> must ensure and maintain records supporting \u00abadequate substantiation of safety\u00bb<\/strong> for each cosmetic product. The law defines this as tests, studies, research, analyses or other information that experts would consider sufficient to support a reasonable certainty of safety under labelled or customary use. FDA and specialist commentators point to toxicological reviews, ingredient safety data, in vitro and in vivo tests, HRIPT and dermatological tests, along with clinical and consumer data where relevant, as valid building blocks.<\/p>\n

\"Scientist<\/p>\n

These records must be in place and available to FDA on request. They are not pre-approved, but a lack of adequate substantiation can support enforcement action, recalls or warning letters. Mirroring the EU, MoCRA also introduces a US Responsible Person<\/strong>, accountable for compliance including safety substantiation and adverse event management.<\/p>\n

In contrast to the EU, MoCRA emphasises post-market oversight<\/strong> backed by mandatory documentation, not a formal pre-market approval or a prescribed report template.<\/p>\n

CPSR vs MoCRA: Similar Goals, Different Mechanics<\/h2>\n

At a high level, both regimes want the same thing: a documented, science-based rationale that the product is safe for consumers. The differences lie in how structured the process is and when it gets checked.<\/p>\n

What they have in common:<\/strong><\/p>\n